Trevi Therapeutics (TRVI) Change in Accured Expenses (2018 - 2026)
Trevi Therapeutics' quarterly Change in Accured Expenses came in at -$1.1 million in Q1 2026, up 28.38% year-on-year from -$837350.8 in Q1 2025, and down 93.69% quarter-over-quarter from -$555000.0 in Q4 2025.
Trevi Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at -$1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 28.38% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$989000.0 (down 149.4% YoY), and the FY2025 full-year result was -$1.4 million, down 155.21% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.1 million, down from -$555000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.2 million in Q3 2024, with the low at -$1.5 million in Q1 2025.
- Average Change in Accured Expenses over 5 years is -$30235.3, with a median of $14000.0 recorded in 2022.
- Peak annual rise in Change in Accured Expenses reached 375.27% in 2024, while the deepest fall reached 3070.83% in 2024.
- Tracing TRVI's Change in Accured Expenses over 5 years: stood at -$1.3 million in 2022, then jumped by 101.85% to $24000.0 in 2023, then tumbled by 3070.83% to -$713000.0 in 2024, then grew by 22.16% to -$555000.0 in 2025, then tumbled by 93.69% to -$1.1 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.1 million (Q1 2026), -$555000.0 (Q4 2025), and $143000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | -1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.08 Mn |
| Mar 31, 2026 | -1.08 Mn |
| Dec 31, 2025 | -555,000.00 |
| Dec 31, 2025 | -555,000.00 |
| Sep 30, 2025 | 143,000.00 |
| Sep 30, 2025 | 143,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Mar 31, 2025 | -1.50 Mn |
| Mar 31, 2025 | -1.50 Mn |
| Dec 31, 2024 | -713,000.00 |
| Dec 31, 2024 | -713,000.00 |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | -940,000.00 |
| Mar 31, 2024 | -940,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 823,000.00 |
| Sep 30, 2023 | 823,000.00 |
| Jun 30, 2023 | -732,000.00 |
| Jun 30, 2023 | -732,000.00 |
| Mar 31, 2023 | -63,000.00 |
| Mar 31, 2023 | -63,000.00 |
| Dec 31, 2022 | -1.30 Mn |
| Dec 31, 2022 | -1.30 Mn |
| Sep 30, 2022 | 307,000.00 |
| Sep 30, 2022 | 307,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Sep 30, 2021 | 90,000.00 |
| Sep 30, 2021 | 90,000.00 |
| Jun 30, 2021 | -757,000.00 |
| Jun 30, 2021 | -757,000.00 |
| Mar 31, 2021 | 447,000.00 |
| Mar 31, 2021 | 447,000.00 |
| Dec 31, 2020 | -1.27 Mn |
| Dec 31, 2020 | -1.27 Mn |
| Sep 30, 2020 | 1.40 Mn |
| Sep 30, 2020 | 1.40 Mn |
| Jun 30, 2020 | -1.64 Mn |
| Jun 30, 2020 | -1.64 Mn |
| Mar 31, 2020 | 1.41 Mn |
| Mar 31, 2020 | 1.41 Mn |
| Dec 31, 2019 | -946,000.00 |
| Dec 31, 2019 | -946,000.00 |
| Sep 30, 2019 | 103,000.00 |
| Sep 30, 2019 | 103,000.00 |
| Jun 30, 2019 | 1.38 Mn |
| Jun 30, 2019 | 1.38 Mn |
| Mar 31, 2019 | 880,000.00 |
| Mar 31, 2019 | 880,000.00 |
| Dec 31, 2018 | 807,000.00 |
| Dec 31, 2018 | 807,000.00 |
| Sep 30, 2018 | 817,000.00 |
| Sep 30, 2018 | 817,000.00 |
| Jun 30, 2018 | -53,000.00 |
| Jun 30, 2018 | -53,000.00 |
| Mar 31, 2018 | -799,000.00 |
| Mar 31, 2018 | -799,000.00 |